Vanguard Group
KURA icon

Vanguard Group’s Kura Oncology KURA Stock Holding History

Vanguard Group’s Portfolio KURA Stock Details KURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$57.2M Buy
5,507,627
+39,105
+0.7% +$410K ﹤0.01% 2093
2025
Q3 		$48.4M Buy
5,468,522
+120,197
+2% +$857K ﹤0.01% 2172
2025
Q2 		$30.9M Buy
5,348,325
+400,090
+8% +$2.45M ﹤0.01% 2353
2025
Q1 		$32.7M Buy
4,948,235
+129,337
+3% +$1.01M ﹤0.01% 2280
2024
Q4 		$42M Buy
4,818,898
+615,211
+15% +$8.85M ﹤0.01% 2237
2024
Q3 		$82.1M Buy
4,203,687
+163,231
+4% +$3.31M ﹤0.01% 1968
2024
Q2 		$83.2M Sell
4,040,456
-25,447
-0.6% -$523K ﹤0.01% 1923
2024
Q1 		$86.7M Buy
4,065,903
+28,212
+0.7% +$548K ﹤0.01% 1939
2023
Q4 		$58.1M Buy
4,037,691
+113,243
+3% +$1.11M ﹤0.01% 2122
2023
Q3 		$35.8M Buy
3,924,448
+275,173
+8% +$2.79M ﹤0.01% 2288
2023
Q2 		$38.6M Buy
3,649,275
+166,055
+5% +$1.96M ﹤0.01% 2308
2023
Q1 		$42.6M Buy
3,483,220
+78,051
+2% +$974K ﹤0.01% 2246
2022
Q4 		$42.3M Buy
3,405,169
+114,968
+3% +$1.67M ﹤0.01% 2259
2022
Q3 		$44.9M Sell
3,290,201
-44,065
-1% -$680K ﹤0.01% 2233
2022
Q2 		$61.1M Buy
3,334,266
+3,920
+0.1% +$56.4K ﹤0.01% 2097
2022
Q1 		$53.6M Buy
3,330,346
+56,638
+2% +$818K ﹤0.01% 2268
2021
Q4 		$45.8M Buy
3,273,708
+9,243
+0.3% +$150K ﹤0.01% 2401
2021
Q3 		$61.1M Sell
3,264,465
-14,185
-0.4% -$267K ﹤0.01% 2249
2021
Q2 		$68.4M Sell
3,278,650
-49,758
-1% -$1.24M ﹤0.01% 2205
2021
Q1 		$94.1M Buy
3,328,408
+95,476
+3% +$3.02M ﹤0.01% 1978
2020
Q4 		$106M Buy
3,232,932
+561,058
+21% +$19.7M ﹤0.01% 1805
2020
Q3 		$81.9M Buy
2,671,874
+1,319
+0% +$29.1K ﹤0.01% 1788
2020
Q2 		$43.5M Buy
2,670,555
+510,630
+24% +$7.37M ﹤0.01% 2072
2020
Q1 		$21.5M Buy
2,159,925
+11,923
+0.6% +$136K ﹤0.01% 2252
2019
Q4 		$29.5M Buy
2,148,002
+22,933
+1% +$340K ﹤0.01% 2343
2019
Q3 		$32.2M Buy
2,125,069
+112,521
+6% +$2M ﹤0.01% 2269
2019
Q2 		$39.6M Buy
2,012,548
+376,172
+23% +$6.24M ﹤0.01% 2223
2019
Q1 		$27.1M Buy
1,636,376
+92,747
+6% +$1.43M ﹤0.01% 2366
2018
Q4 		$21.7M Buy
1,543,629
+87,811
+6% +$1.16M ﹤0.01% 2408
2018
Q3 		$25.5M Buy
1,455,818
+29,785
+2% +$571K ﹤0.01% 2472
2018
Q2 		$26M Buy
1,426,033
+179,947
+14% +$3.05M ﹤0.01% 2450
2018
Q1 		$23.4M Buy
1,246,086
+158,515
+15% +$3.09M ﹤0.01% 2434
2017
Q4 		$16.6M Buy
1,087,571
+102,795
+10% +$1.51M ﹤0.01% 2567
2017
Q3 		$14.7M Buy
984,776
+550,908
+127% +$5.17M ﹤0.01% 2629
2017
Q2 		$4.04M Buy
433,868
+50,033
+13% +$455K ﹤0.01% 3162
2017
Q1 		$3.38M Buy
383,835
+8,619
+2% +$63.2K ﹤0.01% 3204
2016
Q4 		$2.21M Buy
375,216
+2,300
+0.6% +$12.3K ﹤0.01% 3331
2016
Q3 		$2.33M Buy
372,916
+78,750
+27% +$399K ﹤0.01% 3330
2016
Q2 		$797K Hold
294,166
– – ﹤0.01% 3669
2016
Q1 		$1.19M Buy
294,166
+68,499
+30% +$325K ﹤0.01% 3547
2015
Q4 		$1.9M Buy
+225,667
New +$1.78M ﹤0.01% 3414

Other funds holding KURA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Vanguard Group's KURA Position: Q4 2025 in Review

Vanguard Group increased its Kura Oncology (KURA) stake by 0.72% in Q4 2025, buying an estimated $410K and bringing the position to 5,507,627 shares worth $57.2M. The position accounts for ﹤0.01% of the portfolio, ranked #2093.

Vanguard Group first reported a position in KURA in Q4 2015 and has held it in 41 quarters since. The position peaked at $106M in Q4 2020. 215 funds tracked by Wall St. Rank hold KURA as of Q4 2025.

  • Vanguard Group held 5,507,627 shares of Kura Oncology worth $57.2M as of Q4 2025.
  • Vanguard Group bought 39,105 Kura Oncology shares in Q4 2025, an estimated $410K.
  • Kura Oncology made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #2093 holding.
  • Vanguard Group first reported a position in Kura Oncology in Q4 2015 and has held it in 41 quarters since.
  • Vanguard Group's Kura Oncology position peaked at $106M in Q4 2020.
  • 215 funds tracked by Wall St. Rank held Kura Oncology as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.